ATN 081 Specimen Tracking Form A [CRF 100A] Dataset in Treatment De-Intensification and Residual HIV-1 in Adolescents and Young Adults: A Sub-Study of ATN 061 and ATN 071

Data from Specimen Tracking Form A [CRF 100A]
Study Description
A laboratory-based sub-study of ATN 061 and ATN 071 that examined the effect of early treatment (HAART at CD4+ T cells > 350 cells/mm3) followed by treatment de-intensification to atazanavir/ritonavir (ATV/r) monotherapy on steady-state frequencies of replication-competent CD4+ T cell Human Immunodeficiency Virus (HIV)-1 reservoirs or cell-associated infectivity (CAI) and persistent low-level viremia (LLV), and their contribution to successful long-term control of HIV-1 replication among HIV-1 infected adolescents and young adults, ages 18 to 24 years. Some biospecimens are available; for inquiries, please contact Dr. John Sleasman ([e-mail]). HIV-infected adolescents and young adults ages 18-24 years

本数据集数据源自样本追踪表A [病例报告表（Case Report Form, CRF）100A]。

研究概况
本研究为针对ATN 061与ATN 071的实验室子研究，旨在针对18~24岁的HIV感染青少年及青年群体，探究以下内容：当CD4+T淋巴细胞计数＞350个/mm³时启动高效抗反转录病毒治疗（Highly Active Antiretroviral Therapy, HAART），随后采用阿扎那韦/利托那韦（atazanavir/ritonavir, ATV/r）单药治疗降阶方案，对该群体体内具有复制能力的CD4+T细胞源性人类免疫缺陷病毒1型（HIV-1）储存库的稳态频率、细胞相关感染性（Cell-Associated Infectivity, CAI）以及持续性低水平病毒血症（Persistent Low-Level Viremia, LLV）的影响，及其对HIV-1复制实现长期成功控制的贡献。

本研究留存部分生物样本；如有咨询需求，请联系John Sleasman博士（邮箱：[e-mail]）。

本研究的研究对象为18至24岁的HIV感染青少年及青年。